Olaparib could be a safe, effective maintenance therapy in some ovarian cancer patients

by

Ovarian cancer has seen a significant shift in its treatment paradigm with the introduction of poly (ADP-ribose) polymerase (PARP) inhibitors, which are now standard in the maintenance setting following first-line chemotherapy.

Leave A Comment

Your email address will not be published. Required fields are marked *